News - Anti-virals, Biotechnology

Filter

Current filters:

Anti-viralsBiotechnology

Popular Filters

1 to 25 of 151 results

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

27-06-2014

US biotech firm Gilead Sciences revealed this morning it has submitted a New Drug Application to Japan's…

Anti-viralsBiotechnologyGilead SciencesJapanRegulationSovaldi

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

16-06-2014

In draft recommendations published today, UK health care watchdog the National Institute for Health and…

Anti-viralsBiotechnologyGilead SciencesPricingRegulationSovaldiUK

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

Achillion HCV program back on track, as FDA lifts sovaprevir study hold; initiates ACH-3422 dosing

10-06-2014

US drugmaker Achillion has begun dosing ACH-3422, a uridine-analog nucleotide polymerase inhibitor, for…

ACH-3422AchillionAnti-viralsBiotechnologyRegulationResearchsovaprevir

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

French Transparency agency backs Gilead’s new hepatitis C drug Sovaldi

09-06-2014

There was good news for US antivirals major Gilead Sciences, when France’s health technology assessment…

Anti-viralsBiotechnologyFranceGilead SciencesPricingRegulationSovaldi

Biota Pharma plans restructuring following loss of BARDA contract

02-06-2014

USA-based Biota Pharmaceuticals has adopted a plan to restructure the company's operations following…

Anti-viralsBiota PharmaceuticalsBiotechnologyFinanciallaninamivirManagementUSA

Ventrus Biosciences boosted on merger plan with Assembly Pharma

19-05-2014

USA-based Ventrus Biosciences saw its shares leap 9.4% to $1.16 in pre-market trading, as it announced…

Anti-viralsAssembly BiosciencesAssembly PharmaceuticalsBiotechnologyMergers & AcquisitionsVentrus Biosciences

Janssen’s hepatitis C drug Olysio cleared in EU

16-05-2014

Janssen-Cilag International, a subsidiary of US health care giant Johnson & Johnson, says that its next…

Anti-viralsBiotechnologyEuropeJanssen-CilagJohnson & JohnsonOlysioRegulation

Janssen submits sNDA for Olysio in combination with sofosbuvir

Janssen submits sNDA for Olysio in combination with sofosbuvir

08-05-2014

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson, has submitted…

Anti-viralsBiotechnologyGilead SciencesJanssenJohnson & JohnsonOlysioRegulationSovaldiUSA

Gilead’s Sovaldi shows “indication of added benefit for specific patients,” says IQWiG

Gilead’s Sovaldi shows “indication of added benefit for specific patients,” says IQWiG

03-05-2014

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Anti-viralsBiotechnologyGermanyGilead SciencesPricingSovaldi

Professor Raymond Schinazi joins Board of reViral as Non-executive Director

Professor Raymond Schinazi joins Board of reViral as Non-executive Director

28-04-2014

UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor…

Anti-viralsBiotechnologyBoardroomPharmaceuticalreViralUK

Gilead 1st-qtr 2014 sales nearly double, fuelled by Sovaldi, as net income rockets

23-04-2014

US antivirals major Gilead Sciences posted first-quarter 2014 results after markets closed yesterday,…

Anti-viralsBiotechnologyFinancialGilead SciencesSovaldi

NHS England agrees funding for Gilead’s hepatitis C drug Sovaldi

18-04-2014

NHS England has approved an £18.7 million ($31.3 million) investment in a new drug for the treatment…

Anti-viralsBiotechnologyFinancialGilead SciencesHealthcareNorthern EuropeSovaldiUK

HIV market growth to be impacted by patent expiries

16-04-2014

Due to patent expirations of several key therapies, the human immunodeficiency virus (HIV) treatment…

Anti-viralsapricitabineAtriplaBiotechnologycensavudineelvucitabineGilead SciencesMarkets & MarketingPatentsResearchtenofovir alafenamideTruvadaViread

Janssen releases Phase II data for combination of simeprevir and sofosbuvir

Janssen releases Phase II data for combination of simeprevir and sofosbuvir

15-04-2014

US health care giant Johnson & Johnson’s Europe-based subsidiary Janssen has announced positive new…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHealth Medical PharmaHepatitisJanssen BiotechProtease inhibitorsResearchsimeprevirsofosbuvirUSA

Impressive data for once-daily sofosbuvir and ledipasvir treatment of HCV genotype 1

12-04-2014

Strong results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational…

Anti-viralsBiotechnologyGilead SciencesledipasvirResearchsofosbuvirSovaldi

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

Sovaldi effective for retreatment of chronic hepatitis C in patients not cured with prior antiviral therapy

10-04-2014

US antivirals major Gilead Sciences today announced positive findings from an open-label clinical trial…

Anti-viralsBiotechnologyGilead SciencesResearchSovaldi

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

FDA priority review for Gilead’s ledipasvir/sofosbuvir fixed-dose combo for hepatitis C

08-04-2014

US anti-virals major Gilead Sciences says that the US Food and Drug Administration has granted priority…

Anti-viralsBiotechnologyGilead SciencesledipasvirNorth AmericaRegulationsofosbuvirUSA

US lawmakers question price of Gilead’s Sovaldi

US lawmakers question price of Gilead’s Sovaldi

24-03-2014

Three leading US Congressmen have written to John Martin, chief executive of US biotech firm Gilead Sciences,…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPoliticsPricingRegulationSovaldiUSA

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

Idenix Pharma files law suits against Gilead in Europe over sofosbuvir

14-03-2014

US drugmaker Idenix Pharmaceuticals says it has filed patent infringement law suits against biotech firm…

Anti-viralsBiotechnologyGilead SciencesIdenix PharmaceuticalsLegalNorthern EuropePatentssofosbuvirSovaldi

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

“Overwhelming approval” in store for Heplisav if Dynavax delivers sufficient safety data, says analyst

27-02-2014

Despite citing the need for further safety studies, both US and EU regulators have lauded the immunogenicity…

Anti-viralsBiotechnologyDynavax TechnologiesHeplisavRegulationResearchVaccines

AHF claims victory over FDA on Gilead’s PrEP

19-02-2014

The USA-based AIDS Healthcare Foundation (AHF) says it has won another key legal victory late last week…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaRegulationTruvadaUSA

1 to 25 of 151 results

Back to top